Biotricity Stock Earnings Reports

Biotricity reported a transformative fiscal 2025 with continued revenue growth, margin expansion and progress toward profitability. Revenue for Q4 rose 16.5% year-over-year to $3.7M and full-year revenue increased 14.3% to $13.8M. Recurring technology and usage-based subscription revenue now comprise the majority of sales (technology fees = 84.4% of Q4 revenue). Gross margin improved materially (FY gross margin ~76.6%; Q4 margin 80.4%) driven by scale in the cloud/AI platform and lower monitoring costs. Operating expenses were reduced ~24.5% year-over-year, enabling positive adjusted EBITDA of $438k in the last quarter (after noncash adjustments) and continued positive operating cash flow for the third consecutive quarter. Strategic commercial progress includes signing three major GPOs giving access to ~90% of U.S. hospitals (long sales cycles/pilots), expanded Biocore Pro adoption, regulatory approvals in Canada and Saudi Arabia, and pilots with hospital networks. The company emphasizes its Cardiac AI cloud platform (built with partners such as Amazon/AWS and TensorFlow) leveraging >1 trillion heartbeats, pursuing FDA clearance for an AI clinical model, and plans to monetize/analyze the data set over time. Management expects continued margin leverage from economies of scale, further revenue from large hospital/clinic rollouts, and incremental international and DTC (HeartSecure) opportunities, while noting that large GPO deals and pilots will drive material revenue only as they are closed and rolled out.